ÂÜÀòÂÒÂ×

Antoni Ribas is professor of medicine, professor of surgery, and professor of molecular and medical pharmacology at the University of California Los Angeles (UCLA); director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC); director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA; and chair of the Melanoma Committee at SWOG. Antoni is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA. His National Cancer Institute (NCI), state of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options and studies mechanism of action of treatments in patients and the molecular mechanisms of therapy resistance. He is an elected member of the American Society of Clinical Investigation (ASCI), and has been the recipient of the AACR Richard and Hinda Rosenthal Award and an NCI Outstanding Investigator Award.